Company: LIMN
Filing Date: 2025-06-24
Form Type: 8-K
Source: 0001104659-25-062058
Chunk: 0

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On June 24, 2025, Liminatus Pharma, Inc. (the
“ Company”) issued a press release providing an update on its research development programs. A copy of the press release is
furnished as Exhibit 99.1 and is incorporated by reference herein.

The information in Item 7.01 (including Exhibit
99.1) are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of such section nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation
language in such filing.

The Company does not have, and expressly disclaims,
any obligation to release publicly any updates or any changes in the Company’s expectations or any change in events, conditions,
or circumstances on which any forward-looking statement is based, except as required by law.

Item 9.01 Financial Statements and Exhibits.